The function of the Bioinformatics and Data Management Core is to provide the informatics infrastructure, analysis tools and specialized expertise required to support the complex data analysis, integration and storage needs of this Projects and Cores of this grant. Led by Dr. Sarah Cooley, Director of the Masonic Cancer Center Oncology Medical Informatics & Services (OMIS) shared resource, it is composed of two teams providing bioinformatics (UK Team; Anthony Nolan Research Institute) and clinical research data management support (MN team: OMIS). The two groups will meet in person annually and have teleconferences at least every 4 months to ensure the efficient and integrated management of the Core. The MN team is responsible for the development and maintenance of database applications to collect, integrate and report research data generated by the projects for subsequent analysis. In addition they will support and customize the clinical trials management applications to meet the research and regulatory data requirements for the complex (phase I, IND, multi-center) trials in Project 3. The sharing of research samples processed and analyzed by Core D will be coordinated through this Core with a customized sample inventory management tool. Lastly, this team will ensure data quality, data integrity, and data sharing, in compliance with HIPAA regulation and NIH principles. The UK Team will provide bioinformatics support by developing the IPD-KIR Database which will facilitate the work of both the global research community and the grant members. They will continue to collect and curate the KIR sequence data and provide regular updates of this data to allow further development of the typing and sequencing strategies for KIR determination. These developments will include custom bioinformatics tools and applications specifically designed to aid research by other grant members. An expanded suite of bespoke analysis tools will be imbedded to allow advanced analysis for non- Bioinformaticians. A key aim of the IPD project is to provide high quality data that can easily be retrieved and used by non-Bioinformaticians. This can be seen in the work of the IMGT/HLA Database where high level data files, XML, are available for Bioinformaticians, but also tools with easy to use interfaces are provided to allow data analysis possible for a wider range of researchers. They will fully characterize novel KIR sequences detected in Project 1 (SA3) and ensure these data are represented in the public database this will be achieved by conventional cloning methodologies and employing third generation sequencing strategies on the Pacific Biosciences RS II platform. The scientific expertise provided by this team will be invaluable to analyze and interpret immunogenetic data.

Public Health Relevance

This Program Project Grant, which includes four clinical trials and multiple laboratory-based research studies, will generate significant amounts of complex data from multiple sites, all of which must be integrated for definitive analysis. This Core contains Faculty and staff at the University of Minnesota and from the Anthony Nolan Research Institute to develop and support the requisite informatics tools and infrastructure to facilitate sample and data sharing and data analysis to support the basic, translational and clinical research aims.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA111412-12
Application #
9359457
Study Section
Special Emphasis Panel (ZCA1-RPRB-J)
Program Officer
Merritt, William D
Project Start
2005-08-17
Project End
Budget Start
2017-04-01
Budget End
2018-03-31
Support Year
12
Fiscal Year
2017
Total Cost
$67,187
Indirect Cost
$9,460
Name
University of Minnesota Twin Cities
Department
Type
Domestic Higher Education
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Romee, Rizwan; Cooley, Sarah; Berrien-Elliott, Melissa M et al. (2018) First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. Blood 131:2515-2527
Oh, Felix; Todhunter, Deborah; Taras, Elizabeth et al. (2018) Targeting EGFR and uPAR on human rhabdomyosarcoma, osteosarcoma, and ovarian adenocarcinoma with a bispecific ligand-directed toxin. Clin Pharmacol 10:113-121
Rashidi, Armin; Ebadi, Maryam; Said, Bassil et al. (2018) Absence of early HHV-6 reactivation after cord blood allograft predicts powerful graft-versus-tumor effect. Am J Hematol :
Bachanova, Veronika; Sarhan, Dhifaf; DeFor, Todd E et al. (2018) Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells. Cancer Immunol Immunother 67:483-494
de Witte, Moniek A; Sarhan, Dhifaf; Davis, Zachary et al. (2018) Early Reconstitution of NK and ?? T Cells and Its Implication for the Design of Post-Transplant Immunotherapy. Biol Blood Marrow Transplant 24:1152-1162
Pugh, Jason L; Nemat-Gorgani, Neda; Norman, Paul J et al. (2018) Human NK Cells Downregulate Zap70 and Syk in Response to Prolonged Activation or DNA Damage. J Immunol 200:1146-1158
Cichocki, Frank; Wu, Cheng-Ying; Zhang, Bin et al. (2018) ARID5B regulates metabolic programming in human adaptive NK cells. J Exp Med 215:2379-2395
Grzywacz, Bartosz; Moench, Laura; McKenna Jr, David et al. (2018) Natural Killer Cell Homing and Persistence in the Bone Marrow After Adoptive Immunotherapy Correlates With Better Leukemia Control. J Immunother :
Sarhan, Dhifaf; Hippen, Keli L; Lemire, Amanda et al. (2018) Adaptive NK Cells Resist Regulatory T-cell Suppression Driven by IL37. Cancer Immunol Res 6:766-775
Williams, Robin L; Cooley, Sarah; Bachanova, Veronika et al. (2018) Recipient T Cell Exhaustion and Successful Adoptive Transfer of Haploidentical Natural Killer Cells. Biol Blood Marrow Transplant 24:618-622

Showing the most recent 10 out of 108 publications